2-methyl-6-nitrobenzofuran | 87977-31-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 2-methyl-6-nitrobenzofuran
• 英文别名: methyl-2 nitro-6 benzofuranne；6-nitro-2-methylbenzofuran；2-Methyl-6-nitro-1-benzofuran
• CAS: 87977-31-9
• 化学式: C₉H₇NO₃
• 分子量: 177.159
• InChiKey: OARGPFUERLBQDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  59
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methyl-6-nitrobenzofuran 在 aluminum nickel 一水合肼 作用下， 以 乙醇 为溶剂， 以200 mg (81%)的产率得到2-甲基-6-苯并呋喃胺
  参考文献：
  名称：

  Lactam inhibitors of factor Xa and method

  摘要：

  提供了具有以下结构的内酰胺抑制剂 1 ，包括其药用可接受的盐及其所有立体异构体，以及其前药酯，其中n为1至5；和 和R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 ，R 8 ，R 9 ，R 10 ，R 10a ，10 11 和R 12 如本文所定义。这些化合物是因子Xa的抑制剂，因此可用作抗凝剂。还提供了一种用于治疗与血栓相关的心血管疾病的方法。

  公开号：

  US20020025957A1
• 作为产物：
  描述：

  1-nitro-3-(prop-2-yn-1-yloxy)benzene 以 various solvent(s) 为溶剂， 反应 1.0h， 以23%的产率得到2-methyl-6-nitrobenzofuran
  参考文献：
  名称：

  聚乙二醇中芳基炔丙基醚的克莱森重排-显着的取代基和溶剂作用

  摘要：

  在200°C下，聚乙二醇（200）中的芳基炔丙基醚进行克莱森重排，可以提供高收率的产品。含有给电子基团的芳基炔丙基醚产生（2H）-苯并吡喃，而含有吸电子基团的芳基炔丙基醚产生2-甲基苯并呋喃。

  DOI：

  10.1016/s0040-4039(01)99839-9

文献信息

• Sulfonamide anti-arrhythmic agents
  申请人：Pfizer Inc.

  公开号：US04956382A1

  公开（公告）日：1990-09-11

  A series of novel N-alkyl-N-(alkanesulphonamidoheterocyclicmethyl)-4-alkanesulphonamidophene tyl mines have been prepared, including their pharmaceutically acceptable salts and various key novel intermediates therefor. The heterocyclic moiety present in these compounds is a benzo-fused heterocyclic group derived from either benzofuran, benzothiophene, benzoxazole or quinoline, and it is attached to the adjacent methyl group of the molecule by means of the available ring carbon atom which is situated alpha to the hetero atom. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Preferred member compounds include N-methyl-N-(5-methanesulphonamidobenzofur-2-ylmethyl)-4-methanesulphonamid op henethylamine and N-methyl-N-(6-methanesulphonamidoquinol-2-ylmethyl)-4-methanesulphonamidop hen thylamine. Methods for preparing all these compounds from known starting materials are provided.

  已制备了一系列新颖的N-烷基-N-(烷磺酰胺杂环甲基)-4-烷磺酰胺苯基矿物，包括它们的药用可接受的盐和各种关键的新颖中间体。这些化合物中存在的杂环基团是来源于苯并呋喃、苯并噻吩、苯并噁唑或喹啉的苯并杂环基团，并且通过可用的环碳原子连接到分子的相邻甲基基团，该环碳原子位于异原子的α位。这些特定化合物在治疗中非常有效，可用作高效的抗心律失常药物，因此对于治疗各种心脏心律失常具有价值。首选的成员化合物包括N-甲基-N-(5-甲磺酰胺基苯并呋喃-2-基甲基)-4-甲磺酰胺苯基乙胺和N-甲基-N-(6-甲磺酰胺基喹啉-2-基甲基)-4-甲磺酰胺苯基乙胺。提供了从已知起始材料制备所有这些化合物的方法。
• Quinolyl substituted indane sulfonamides and their use as
  申请人：Pfizer Inc.

  公开号：US04829071A1

  公开（公告）日：1989-05-09

  Novel 5-alkanesulphonamido-2-[N-(alkanesulphonamidoheterocyclicmethyl-N-methylam ino]indane compounds have been prepared, including their pharmaceutically acceptable salts and various key novel intermediates therefor. The heterocyclic moiety present in these compounds is a benzofused heterocyclic group derived from either benzofuran or quinoline, and it is attached to the adjacent methyl group of the molecule by means of the available ring carbon atom which is situated alpha to the hetero atom. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. The most preferred member compound is 5-methylanesulphonamido-2-[N-(5-methanesulphonamidobenzofur-2-ylmethyl)-N- methylamino]idane. Methods for preparing these compounds from known starting materials are provided.

  已制备了新颖的5-烷基磺酰胺基-2-[N-(烷基磺酰胺基杂环甲基-N-甲基氨基]茚烷化合物，包括它们的药用盐和各种关键的新颖中间体。这些化合物中的杂环基团是从苯并呋喃或喹啉中派生的苯并杂环基团，并且通过位于异原子α位的可用环碳原子连接到分子的相邻甲基基团上。这些化合物在治疗中作为抗心律失常药物具有用途，因此对于治疗各种心脏心律失常具有价值。最受欢迎的成员化合物是5-甲基磺酰胺基-2-[N-(5-甲烷磺酰胺基苯并呋喃-2-基甲基)-N-甲基氨基]茚烷。提供了从已知起始材料制备这些化合物的方法。
• [EN] LACTAM INHIBITORS OF FACTOR XA AND METHOD<br/>[FR] INHIBITEURS DE LACTAMES DU FACTEUR XA ET PROCEDE ASSOCIE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2001096331A1

  公开（公告）日：2001-12-20

  Lactam inhibitors are provided which have the structure (I) including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is l to 5; and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R10a, R11 and R12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.

  提供了具有结构（I）的内酰胺抑制剂，包括其药学上可接受的盐和所有立体异构体，以及其前药酯，其中n为1至5; R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R10a、R11和R12如本文所定义。这些化合物是因子Xa的抑制剂，因此可用作抗凝剂。还提供了一种用于治疗与血栓有关的心血管疾病的方法。
• Benzoxazole sulfonamide anti-arrhythmic agents
  申请人：Pfizer Inc.

  公开号：US05158964A1

  公开（公告）日：1992-10-27

  A series of novel N-alkyl N-(alkanesulphonamidoheterocyclicmethyl)-4-alkanesulphonamidophenethylamin es have been prepared, including their pharmaceutically acceptable salts and various key novel intermediates therefor. The heterocyclic moiety present in these compounds is a benzo-fused heterocyclic group derived from either benzofuran, benzothiophene, benzoxazole or quinoline, and it is attached to the adjacent methyl group of the molecule by means of the available ring carbon atom which is situated alpha to the hetero atom. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Preferred member compounds include N-methyl-N-(5 methanesulphonamidobenzofur-2-ylmethyl)-4-methanesulphonamidophenethylamin e and N-methyl-N-(6 methanesulphonamidoquinol-2-ylmethyl)-4-methanesulphonamidophenethylamine. Methods for preparing all these compounds from known starting materials are provided.

  一系列新型的N-烷基N-(烷基磺酰胺杂环甲基)-4-烷基磺酰胺苯乙胺已被制备，包括它们的药学上可接受的盐和各种关键的新型中间体。这些化合物中存在的杂环基团是从苯并呋喃、苯并噻吩、苯并噁唑或喹啉中派生出来的苯并杂环基团，并且通过可用的环碳原子与分子中毗邻的甲基基团连接，该环碳原子位于杂原子α位。这些特定的化合物在治疗中是有用的，因为它们是高效的抗心律失常药物，因此对于治疗各种心脏心律失常具有价值。首选的成员化合物包括N-甲基-N-(5-甲烷磺酰胺基苯并呋喃-2-基甲基)-4-甲烷磺酰胺苯乙胺和N-甲基-N-(6-甲烷磺酰胺基喹啉-2-基甲基)-4-甲烷磺酰胺苯乙胺。提供了从已知起始材料制备所有这些化合物的方法。
• Quinolinyl sulfonamide anti-arrhythmic agents and use thereas
  申请人：Pfizer Inc.

  公开号：US05055473A1

  公开（公告）日：1991-10-08

  A series of novel N-alkyl-N-(alkanesulphonamidoheterocyclicmethyl) -4-alkanesulphonamidophenethylamines have been prepared, including their pharmaceutically acceptable salts and various key novel intermediates therefor. The heterocyclic moiety present in these compounds is a benzo-fused heterocyclic group derived from either benzofuran, benzothiophene, benzoxazole or quinoline, and it is attached to the adjacent methyl group of the molecule by means of the available ring carbon atom which is situated alpha to the hetero atom. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Preferred member compounds include N-methyl-N-(5-methanesulphonamidobenzofur-2-ylmethyl)-4 -methanesulphonamidophenethylamine and N-methyl-N-(6- methanesulphonamidoquinol-2-ylmethyl)-4-methane-sulphonamidophenethylamine . Methods for preparing all these compounds from known starting materials are provided.

  一系列新型N-烷基-N-(烷磺酰胺杂环甲基)-4-烷磺酰胺基苯乙胺已经制备出来，包括它们的药学上可接受的盐和各种关键的新型中间体。这些化合物中存在的杂环基团是从苯并呋喃、苯并噻吩、苯并噁唑或喹啉中派生出来的苯并杂环基团，并通过位于杂原子α位的可用环碳原子连接到分子的相邻甲基基团上。这些特定的化合物在治疗中是有用的，因为它们是高效的抗心律失常剂，因此对于治疗各种心脏心律失常具有价值。优选的成员化合物包括N-甲基-N-(5-甲烷磺酰胺基苯并呋喃-2-基甲基)-4-甲烷磺酰胺基苯乙胺和N-甲基-N-(6-甲烷磺酰胺基喹啉-2-基甲基)-4-甲烷磺酰胺基苯乙胺。提供了从已知起始材料制备所有这些化合物的方法。